[Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab]
Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)
Record ID 32010000707
Catalan
Authors' objectives:
To evaluate the efficacy, safety and efficiency of ofatumumab compared to any other therapeutic alternative, including placebo, in the treatment of adult patients with CLL refractory to fludarabine and alemtuzumab.
Authors' recommendations:
Ofatumumab has shown benefits in terms of disease control in patients with CLL refractory to fludarabine and alemtuzumab. The most frequent adverse events are reactions relating to infusions and infections.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/ofatumumab_leucemia_aiaqs2011ca.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Technology Assessment and Research (CAHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.